Prestige Brands completes purchase of Hydralyte Prestige Brands Holdings has closed the previously announced acquisition of Hydralyte from the Hydration Pharmaceuticals Trust of Victoria, Australia. The transaction was finalized pursuant to the original terms of the purchase agreement announced on April 15. As previously mentioned, the acquisition of Hydralyte is projected to double the revenues of Care to approximately A$50M, and is expected to be accretive to Prestige’s EPS for FY15, exclusive of transaction, integration and purchase accounting items. Prestige acquired Care in July 2013.
Prestige Brands sees FY15 EPS $1.75-$1.85, consensus $1.80 Says on track to deliver FY15 sales growth 15%-18% and adjusted free cash flow of approximately $150M. Comments from slides that will be presented at the Morgan Stanley Global Consumer Conference.